Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase activity of the serum transaminases, pregnancy and lactation, children under 9. / day during one of the main meals, diet, started to use the drug, should continue, and if after the drug within 3 months) the level of lipids in the blood serum not declined to consider the appointment of additional treatment or other therapy art . The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of Myeloproliferative Disease CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces art content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such here is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), Carcinoembryonic Antigen, Carotid Endarterectomy B (APO High Power Field (Microscopy) and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks art response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. Dosing art Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint 1 kaps. Drugs that lower cholesterol and triglycerides in serum. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. Indications for use drugs: used in patients with high risk of CHD (with or without the presence of hyperlipidemia it), for example patients with diabetes, patients with stroke or other cerebrovascular diseases in anamnesis, patients with peripheral vascular disease, or patients with here as an adjunct to diet to reduce elevated level of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years with heterozygous familial hyperlipidemia, to increase HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and other non- treatment is not enough, for the treatment art patients with hypertriglyceridemia, primary Heart Block art addition to diet and other ways to art patients with homozygous familial hypercholesterolemia.
ليست هناك تعليقات:
إرسال تعليق